COMMUNIQUÉS West-GlobeNewswire

MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
10/08/2026
The reported resubmission of the New Drug Application will initiate a new evaluation of the treatment’s safety and efficacy for potential FDA approval Recently updated FDA guidance, Psychedelic Drugs: Considerations for [...]
HRC Technology Solutions LLC Achieves SOC 1 Type 2 and SOC 2 Type 2 Compliance, Reinforcing Secure, AI-Driven Revenue Cycle Management
10/08/2026
SOUTHLAKE, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- HRC Technology Solutions LLC today announced it has achieved SOC 1 Type 2 and SOC 2 Type 2 compliance, independently assessed by ControlCase as its Qualified Security [...]
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
10/08/2026
Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting Announced a [...]
Mesa Labs Announces First Quarter Results
10/08/2026
LAKEWOOD, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
10/08/2026
- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep [...]
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
10/08/2026
Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 [...]
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer [...]
InspireMD to Announce Second Quarter 2026 Financial Results
10/08/2026
MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced it will issue its [...]
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
10/08/2026
Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval [...]
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
10/08/2026
Expanded collaboration applies multiplex protein profiling across 86,000 additional samples, enabling researchers to move beyond single biomarkers toward a precision-medicine understanding of disease heterogeneity, [...]
TELA Bio Reports Second Quarter 2026 Financial Results
10/08/2026
MALVERN, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
10/08/2026
FREMONT, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for [...]
Bionano Reports Second Quarter 2026 Results and Provides a Business Update
10/08/2026
Conference call today, August 10, 2026, at 4:30 PM ET SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2026. "Our [...]
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
10/08/2026
– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – Favorable long - term safety and tolerability profile remained consistent with [...]
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
10/08/2026
Discussions with FDA advance toward expected marketing authorization for GraftAssureDx FDA completes current portion of substantive review in a timely manner Favorable Medicare reimbursement policy issued in July [...]
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
10/08/2026
Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and available-for- [...]

Pages